Obesity pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.
ClassNone selected
MechanismNone selected
No arms selected. Choose a drug, an arm, or a preset.
299 of 2118 arms with a reported figure. Choose arms to narrow the chart.
| Drug, trial | Population | Dose | Weeks | Estimand | Comparator | Baseline weight | Mean change | Comparator delta | HbA1c |
|---|---|---|---|---|---|---|---|---|---|
| Semaglutide 2.4 mgSTEP 1 | Obesity or overweight | 2.4 mg | 68 | ITT | placebo | n/r | -14.9% | -12.4 | n/r |
| Semaglutide Semaglutide placeboSTEP 1 | Obesity or overweight | n/r | 68 | ITT | This arm is placebo | n/r | -2.4% | n/r | n/r |
| Semaglutide 7.2 mgSTEP UP | Obesity or overweight | 7.2 mg | 72 | ITT | placebo | n/r | -18.8% | -14.9 | n/r |
| Semaglutide 2.4 mgSTEP UP | Obesity or overweight | 2.4 mg | 72 | ITT | placebo | n/r | -15.5% | n/r | n/r |
| Semaglutide PlaceboSTEP UP | Obesity or overweight | n/r | 72 | ITT | This arm is placebo | n/r | -3.9% | n/r | n/r |
| Semaglutide SemaglutideSELECT | Obesity or overweight | n/r | 4 | ITT | placebo | n/r | n/r | n/r | -0.31 Percentage of HbA1c |
| Semaglutide Placebo (semaglutide)SELECT | Obesity or overweight | n/r | 4 | ITT | This arm is placebo | n/r | n/r | n/r | 0.01 Percentage of HbA1c |
| Semaglutide 1.0 mgSTEP 2 | Obesity or overweight | 1.0 mg | 4 | ITT | placebo | n/r | n/r | n/r | -1.5 Percentage point of HbA1c |
| Semaglutide 2.4 mgSTEP 2 | Obesity or overweight | 2.4 mg | 4 | ITT | placebo | n/r | n/r | n/r | -1.7 Percentage point of HbA1c |
| Semaglutide Semaglutide placebo I/IISTEP 2 | Obesity or overweight | n/r | 4 | ITT | This arm is placebo | n/r | n/r | n/r | -0.3 Percentage point of HbA1c |
| Semaglutide SemaglutideSTEP 4 | Obesity or overweight | n/r | 20 | Efficacy | placebo | n/r | -8.3% | n/r | n/r |
| Semaglutide PlaceboSTEP 4 | Obesity or overweight | n/r | 20 | Efficacy | This arm is placebo | n/r | 6.5% | n/r | n/r |
| Semaglutide 2.4 mgSTEP 4 | Obesity or overweight | 2.4 mg | 20 | ITT | n/r | n/r | n/r | n/r | -0.2 Percentage point of HbA1c |
| Semaglutide Placebo, in trialSTEP 4 | Obesity or overweight | n/r | 20 | ITT | This arm is placebo | n/r | n/r | n/r | 0.1 Percentage point of HbA1c |
| Semaglutide 15 mgSURMOUNT-5 | Obesity or overweight | 15 mg | 72 | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mgSURMOUNT-5 | Obesity or overweight | 2.4 mg | 72 | n/r | n/r | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mgSTEP HFpEF DM | T2D only | 2.4 mg | 1 | ITT | placebo | n/r | n/r | n/r | -0.8 Percentage of HbA1c |
| Semaglutide Semaglutide placebo OWSTEP HFpEF DM | T2D only | n/r | 1 | ITT | This arm is placebo | n/r | n/r | n/r | 0.1 Percentage of HbA1c |
| Semaglutide SemaglutideSTEP 3 | Obesity or overweight | n/r | 4 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| Semaglutide Semaglutide placeboSTEP 3 | Obesity or overweight | n/r | 4 | Efficacy | This arm is placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mgSTEP 3 | Obesity or overweight | 2.4 mg | n/r | ITT | n/r | n/r | n/r | n/r | -0.5 Percentage point of HbA1c |
| Semaglutide Placebo, in trialSTEP 3 | Obesity or overweight | n/r | n/r | ITT | This arm is placebo | n/r | n/r | n/r | -0.3 Percentage point of HbA1c |
| Semaglutide Insuline glargine U100 (reduced) + semaglutideA Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S | Obesity + T2D | n/r | n/r | n/r | n/r | n/r | n/r | n/r | -1.37 Percentage point of HbA1c |
| Semaglutide Insuline glargine U100 (titrated)A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S | Obesity + T2D | n/r | n/r | n/r | n/r | n/r | n/r | n/r | -0.65 Percentage point of HbA1c |
| Semaglutide SemaglutideSTEP-HFpEF | Obesity or overweight | n/r | 59 | ITT | placebo | n/r | n/r | n/r | n/r |
| Semaglutide Placebo (semaglutide)STEP-HFpEF | Obesity or overweight | n/r | 59 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Semaglutide 7.2 mgA Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Obesity + T2D | 7.2 mg | 72 | n/r | placebo | n/r | n/r | n/r | -1.8 Percentage of HbA1c |
| Semaglutide 2.4 mgA Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Obesity + T2D | 2.4 mg | 72 | n/r | placebo | n/r | n/r | n/r | -1.7 Percentage of HbA1c |
| Semaglutide PlaceboA Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Obesity + T2D | n/r | 72 | n/r | This arm is placebo | n/r | n/r | n/r | -0.3 Percentage of HbA1c |
| Semaglutide 2.4 mgResearch Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Obesity or overweight | 2.4 mg | n/r | ITT | placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mgResearch Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Obesity or overweight | 2.4 mg | n/r | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mgSTEP 6 | Obesity or overweight | 2.4 mg | 68 | ITT | placebo | n/r | n/r | n/r | -1 Percentage of HbA1c |
| Semaglutide 2.4 mgSTEP 6 | Obesity or overweight | 2.4 mg | 68 | ITT | This arm is placebo | n/r | n/r | n/r | 0 Percentage of HbA1c |
| Semaglutide 1.7 mgSTEP 6 | Obesity or overweight | 1.7 mg | 68 | ITT | placebo | n/r | n/r | n/r | -0.9 Percentage of HbA1c |
| Semaglutide 1.7 mgSTEP 6 | Obesity or overweight | 1.7 mg | 68 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Semaglutide SemaglutideSTEP7 | Obesity + T2D | n/r | 44 | ITT | placebo | n/r | n/r | n/r | -0.8 Percentage of HbA1c |
| Semaglutide Placebo (semaglutide)STEP7 | Obesity + T2D | n/r | 44 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage of HbA1c |
| Semaglutide SemaglutideSTEP 5 | Obesity or overweight | n/r | 4 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| Semaglutide PlaceboSTEP 5 | Obesity or overweight | n/r | 4 | Efficacy | This arm is placebo | n/r | n/r | n/r | n/r |
| Semaglutide 2.4 mgSTEP 5 | Obesity or overweight | 2.4 mg | n/r | ITT | n/r | n/r | n/r | n/r | -0.5 Percent of glycated haemoglobin |
| Semaglutide Placebo, in trialSTEP 5 | Obesity or overweight | n/r | n/r | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percent of glycated haemoglobin |
| Semaglutide PlaceboSTEP12 | Obesity or overweight | n/r | 44 | n/r | This arm is placebo | n/r | n/r | n/r | 0 Percentage of HbA1c |
| Semaglutide 2.4 mgSTEP12 | Obesity or overweight | 2.4 mg | n/r | n/r | n/r | n/r | n/r | n/r | -0.4 Percentage of HbA1c |
| Semaglutide SemaglutideSTEP 10 | Obesity or overweight | n/r | 52 | ITT | placebo | n/r | n/r | n/r | -0.4 Percentage of HbA1c |
| Semaglutide Placebo (semaglutide)STEP 10 | Obesity or overweight | n/r | 52 | ITT | This arm is placebo | n/r | n/r | n/r | 0.1 Percentage of HbA1c |
| Semaglutide SemaglutideA Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Obesity or overweight | n/r | 16 | ITT | placebo | n/r | n/r | n/r | -0.4 Percentage of HbA1c |
| Semaglutide PlaceboA Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Obesity or overweight | n/r | 16 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage of HbA1c |
| Semaglutide 2.4 mgResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity or overweight | 2.4 mg | 50 | ITT | placebo | n/r | n/r | n/r | -0.4 Percentage of HbA1c |
| Semaglutide PlaceboResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity or overweight | n/r | 50 | ITT | This arm is placebo | n/r | n/r | n/r | 0 Percentage of HbA1c |
| Semaglutide Semaglutide, on treatmentResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity or overweight | n/r | 44 | Efficacy | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Placebo, on treatmentResearch Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Obesity or overweight | n/r | 44 | Efficacy | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboSURMOUNT-1 | Obesity, no T2D | n/r | 72 | ITT | This arm is placebo | n/r | -3.1% | n/r | n/r |
| Tirzepatide 5 mgSURMOUNT-1 | Obesity, no T2D | 5 mg | 72 | ITT | placebo | n/r | -15% | -11.9 | n/r |
| Tirzepatide 10 mgSURMOUNT-1 | Obesity, no T2D | 10 mg | 72 | ITT | placebo | n/r | -19.5% | -16.4 | n/r |
| Tirzepatide 15 mgSURMOUNT-1 | Obesity, no T2D | 15 mg | 72 | ITT | placebo | n/r | -20.9% | -17.8 | n/r |
| Tirzepatide 15 mgSURMOUNT-2 | Obesity + T2D | 15 mg | 79 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboSURMOUNT-2 | Obesity + T2D | n/r | 79 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mgSURMOUNT-2 | Obesity + T2D | 10 mg | 72 | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide (lead-in)SURMOUNT-4 | Obesity or overweight | n/r | 36 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTDSURMOUNT-4 | Obesity or overweight | n/r | 36 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboSURMOUNT-4 | Obesity or overweight | n/r | 36 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide TirzepatideA Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Obesity or overweight | n/r | 4 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboA Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Obesity or overweight | n/r | 4 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide TirzepatideSURMOUNT-3 | Obesity or overweight | n/r | 72 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboSURMOUNT-3 | Obesity or overweight | n/r | 72 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD_GPI1SURMOUNT-OSA | Obesity or overweight | n/r | 52 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo_GPI1SURMOUNT-OSA | Obesity or overweight | n/r | 52 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Tirzepatide MTD_GPI2SURMOUNT-OSA | Obesity or overweight | n/r | 52 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Placebo_GPI2SURMOUNT-OSA | Obesity or overweight | n/r | 52 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mgSURMOUNT-J | Obesity or overweight | 15 mg | 72 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboSURMOUNT-J | Obesity or overweight | n/r | 72 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mgSURMOUNT-J | Obesity or overweight | 10 mg | 72 | n/r | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide 15 mgSURMOUNT-CN | Obesity or overweight | 15 mg | 52 | n/r | placebo | n/r | n/r | n/r | n/r |
| Tirzepatide PlaceboSURMOUNT-CN | Obesity or overweight | n/r | 52 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tirzepatide 10 mgSURMOUNT-CN | Obesity or overweight | 10 mg | 52 | n/r | n/r | n/r | n/r | n/r | n/r |
| Orforglipron PlaceboATTAIN-2 | Obesity + T2D | n/r | 72 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Orforglipron 6 mgATTAIN-2 | Obesity + T2D | 6 mg | 72 | n/r | placebo | n/r | n/r | n/r | n/r |
| Orforglipron 12 mgATTAIN-2 | Obesity + T2D | 12 mg | 72 | n/r | placebo | n/r | n/r | n/r | n/r |
| Orforglipron Placebo QDATTAIN-J | Obesity or overweight | n/r | 72 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Orforglipron 6 mgATTAIN-J | Obesity or overweight | 6 mg | 72 | n/r | placebo | n/r | n/r | n/r | n/r |
| Orforglipron 12 mgATTAIN-J | Obesity or overweight | 12 mg | 72 | n/r | placebo | n/r | n/r | n/r | n/r |
| Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mgREDEFINE 1 | Obesity, no T2D | cagrilintide 2.4 mg and semaglutide 2.4 mg | 68 | n/r | placebo | n/r | -20.4% | -17.3 | n/r |
| Cagrilintide/semaglutide Placebo s.c.REDEFINE 1 | Obesity, no T2D | n/r | 68 | n/r | This arm is placebo | n/r | -3% | n/r | n/r |
| Retatrutide 4 mgTRIUMPH-1 | Obesity, no T2D | 4 mg | 80 | ITT | placebo | n/r | -17.6% | n/r | n/r |
| Retatrutide 9 mgTRIUMPH-1 | Obesity, no T2D | 9 mg | 80 | ITT | placebo | n/r | -23.7% | -19.8 | n/r |
| Retatrutide 12 mgTRIUMPH-1 | Obesity, no T2D | 12 mg | 80 | ITT | placebo | n/r | -25% | -21 | n/r |
| Retatrutide PlaceboTRIUMPH-1 | Obesity, no T2D | n/r | 80 | ITT | This arm is placebo | n/r | -3.9% | n/r | n/r |
| Survodutide 3.6 mgSYNCHRONIZE-1 | Obesity + T2D | 3.6 mg | 76 | ITT | placebo | n/r | -12.2% | n/r | n/r |
| Survodutide 6.0 mgSYNCHRONIZE-1 | Obesity + T2D | 6.0 mg | 76 | ITT | placebo | n/r | -13% | n/r | n/r |
| Survodutide PlaceboSYNCHRONIZE-1 | Obesity + T2D | n/r | 76 | ITT | This arm is placebo | n/r | -5.4% | n/r | n/r |
| Survodutide 0.6 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Obesity or overweight | 0.6 mg | 46 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| Survodutide Placebo groupA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Obesity or overweight | n/r | 46 | Efficacy | This arm is placebo | n/r | n/r | n/r | n/r |
| Survodutide 2.4 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Obesity or overweight | 2.4 mg | 46 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| Survodutide 3.6 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Obesity or overweight | 3.6 mg | 46 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| Survodutide 4.8 mgA Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight | Obesity or overweight | 4.8 mg | 46 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| VK2735 2.5 mgVENTURE | Obesity, no T2D | 2.5 mg | 13 | n/r | placebo | n/r | -9.1% | n/r | n/r |
| VK2735 15 mgVENTURE | Obesity, no T2D | 15 mg | 13 | n/r | placebo | n/r | -14.7% | n/r | n/r |
| VK2735 Placebo 13 weeksVENTURE | Obesity, no T2D | n/r | 13 | n/r | This arm is placebo | n/r | -1.7% | n/r | n/r |
| Eloralintide PlaceboNCT06230523 | Obesity, no T2D | n/r | 48 | Efficacy | This arm is placebo | n/r | -0.4% | n/r | n/r |
| Eloralintide 1 mgNCT06230523 | Obesity, no T2D | 1 mg | 48 | Efficacy | placebo | n/r | -9% | n/r | n/r |
| Eloralintide 3 mgNCT06230523 | Obesity, no T2D | 3 mg | 48 | Efficacy | placebo | n/r | -12% | n/r | n/r |
| Eloralintide 6 mgNCT06230523 | Obesity, no T2D | 6 mg | 48 | Efficacy | placebo | n/r | -18% | n/r | n/r |
| Eloralintide 9 mgNCT06230523 | Obesity, no T2D | 9 mg | 48 | Efficacy | placebo | n/r | -20% | n/r | n/r |
| Berobenatide PlaceboVESPER-1 | Obesity or overweight | n/r | 28 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Dulaglutide Dulaglutide ArmMetabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients | Stress Hyperglycemia | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Dulaglutide Placebo ArmMetabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients | Stress Hyperglycemia | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Exenatide Group AEffect on Weight Loss of Exenatide Versus Placebo | T2D only | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Exenatide Group BEffect on Weight Loss of Exenatide Versus Placebo | T2D only | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Exenatide ExenatideThe Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects | Obesity or overweight | n/r | 5 | n/r | placebo | n/r | n/r | n/r | n/r |
| Exenatide PlaceboThe Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects | Obesity or overweight | n/r | 5 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Exenatide Exenatide once weekly (EQW )EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Obesity or overweight | n/r | 4 | n/r | n/r | n/r | 3.8% | n/r | n/r |
| Exenatide Dapagliflozin (DAPA)EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Obesity or overweight | n/r | 4 | n/r | n/r | n/r | 1.5% | n/r | n/r |
| Exenatide EQW plus DAPAEQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Obesity or overweight | n/r | 4 | n/r | n/r | n/r | 6.9% | n/r | n/r |
| Exenatide Dapagliflozin plus Glucophage (MET ER)EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Obesity or overweight | n/r | 4 | n/r | n/r | n/r | 1.7% | n/r | n/r |
| Exenatide Phentermine /Topiramate (PHEN/ TPM) EREQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Obesity or overweight | n/r | 4 | n/r | n/r | n/r | 8.1% | n/r | n/r |
| Exenatide Exenatide once weekly extended-releaseECHO | Obesity or overweight | n/r | 36 | n/r | placebo | n/r | 1.7% | n/r | n/r |
| Exenatide Matching placeboECHO | Obesity or overweight | n/r | 36 | n/r | This arm is placebo | n/r | 3.5% | n/r | n/r |
| Exenatide Group AA Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | Obesity or overweight | n/r | 24 | n/r | placebo | n/r | n/r | n/r | n/r |
| Exenatide Group BA Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients | Obesity or overweight | n/r | 24 | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0mgEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Obesity or overweight | 3.0mg | 68 | n/r | placebo | n/r | 0.69% | n/r | n/r |
| Liraglutide 3.0mgEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Obesity or overweight | 3.0mg | 68 | n/r | n/r | n/r | 2.91% | n/r | n/r |
| Liraglutide Liraglutide Placebo, no Pre-diabetesEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Obesity or overweight | n/r | 68 | n/r | This arm is placebo | n/r | 0.28% | n/r | n/r |
| Liraglutide Liraglutide Placebo, Pre-diabetesEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Obesity or overweight | n/r | 68 | Efficacy | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mgEffect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Obesity or overweight | 3.0 mg | 56 | Efficacy | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mgEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Obesity or overweight | 3.0 mg | 56 | n/r | placebo | n/r | 2.3% | n/r | -1.3 percentage point change of HbA1c |
| Liraglutide 1.8 mgEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Obesity or overweight | 1.8 mg | 56 | n/r | placebo | n/r | 2% | n/r | -1.1 percentage point change of HbA1c |
| Liraglutide PlaceboEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Obesity or overweight | n/r | 56 | n/r | This arm is placebo | n/r | -0.1% | n/r | -0.3 percentage point change of HbA1c |
| Liraglutide 3.0 mgComparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Obesity or overweight | 3.0 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Liraglutide PlaceboComparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mgSCALE™ Insulin | Obesity or overweight | 3.0 mg | 56 | Efficacy | placebo | n/r | n/r | n/r | -1.1 Percentage of HbA1c |
| Liraglutide PlaceboSCALE™ Insulin | Obesity or overweight | n/r | 56 | Efficacy | This arm is placebo | n/r | n/r | n/r | -0.5 Percentage of HbA1c |
| Liraglutide 3.0 mgEffect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Obesity or overweight | 3.0 mg | 32 | n/r | placebo | n/r | n/r | n/r | -0.36 percentage of glycosylated haemoglobin |
| Liraglutide PlaceboEffect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Obesity or overweight | n/r | 32 | n/r | This arm is placebo | n/r | n/r | n/r | -0.17 percentage of glycosylated haemoglobin |
| Liraglutide SemaglutideSTEP 8 | Obesity or overweight | n/r | 68 | ITT | placebo | n/r | n/r | n/r | -0.3 Percenatge of HbA1c |
| Liraglutide LiraglutideSTEP 8 | Obesity or overweight | n/r | 68 | ITT | placebo | n/r | n/r | n/r | -0.1 Percenatge of HbA1c |
| Liraglutide Placebo (liraglutide)STEP 8 | Obesity or overweight | n/r | 68 | ITT | This arm is placebo | n/r | n/r | n/r | 0.1 Percenatge of HbA1c |
| Liraglutide LiraglutideSCALE™ IBT | Obesity or overweight | n/r | 56 | Efficacy | placebo | n/r | n/r | n/r | n/r |
| Liraglutide PlaceboSCALE™ IBT | Obesity or overweight | n/r | 56 | Efficacy | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mgSCALE™ IBT | Obesity or overweight | 3.0 mg | 56 | ITT | n/r | n/r | n/r | n/r | -0.2 percentage |
| Liraglutide Placebo, in trialSCALE™ IBT | Obesity or overweight | n/r | 56 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 percentage |
| Liraglutide LiraglutideEffect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | -0.1 Percentage of HbA1c |
| Liraglutide PlaceboEffect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | 0 Percentage of HbA1c |
| Liraglutide Metformin XR plus liraglutideCombined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | T2D only | n/r | 84 | n/r | placebo | n/r | -7.2% | n/r | n/r |
| Liraglutide Metformin XR plus placeboCombined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | T2D only | n/r | 84 | n/r | This arm is placebo | n/r | -3.1% | n/r | n/r |
| Liraglutide Liraglutide Pen Injector (Saxenda)SAXAPCOS | Obesity + T2D | n/r | 1 | n/r | placebo | n/r | 5.7% | n/r | n/r |
| Liraglutide Placebo liraglutide pen injectorSAXAPCOS | Obesity + T2D | n/r | 1 | n/r | This arm is placebo | n/r | 1.4% | n/r | n/r |
| Liraglutide LiraglutideEffect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | -0.2 Percentage point of HbA1c |
| Liraglutide PlaceboEffect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | 0 Percentage point of HbA1c |
| Liraglutide 0.05 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Obesity or overweight | 0.05 mg | 52 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 0.1 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Obesity or overweight | 0.1 mg | 52 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 0.2 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Obesity or overweight | 0.2 mg | 52 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 0.3 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Obesity or overweight | 0.3 mg | 52 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 0.4 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Obesity or overweight | 0.4 mg | 52 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mgInvestigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus | Obesity or overweight | 3.0 mg | 52 | ITT | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide Placebo + MetforminA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | T2D only | n/r | 14 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Liraglutide Liraglutide + MetforminA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | T2D only | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Liraglutide 100 mcgA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | T2D only | 100 mcg | 14 | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 200 mcgA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | T2D only | 200 mcg | 14 | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 300 mcgA Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes | T2D only | 300 mcg | 14 | n/r | n/r | n/r | n/r | n/r | n/r |
| Liraglutide 2.4 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 2.4 mg | 26 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage point of HbA1c |
| Liraglutide 4.5 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 4.5 mg | 26 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage point of HbA1c |
| Liraglutide 1.2 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 1.2 mg | 26 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage point of HbA1c |
| Liraglutide 0.6 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 0.6 mg | 26 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage point of HbA1c |
| Liraglutide 0.3 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 0.3 mg | 26 | ITT | This arm is placebo | n/r | n/r | n/r | 0 Percentage point of HbA1c |
| Liraglutide 3.0 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 3.0 mg | 26 | ITT | placebo | n/r | n/r | n/r | -0.3 Percentage point of HbA1c |
| Liraglutide 3.0 mgResearch Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. | Obesity or overweight | 3.0 mg | 26 | ITT | This arm is placebo | n/r | n/r | n/r | -0.1 Percentage point of HbA1c |
| Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Obesity or overweight | 3.0 mg | n/r | n/r | n/r | n/r | n/r | n/r | 5.6 percentage (%) of total haemoglobin |
| Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Obesity or overweight | 3.0 mg | n/r | n/r | placebo | n/r | n/r | n/r | 5.58 percentage (%) of total haemoglobin |
| Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Obesity or overweight | 3.0 mg | n/r | n/r | placebo | n/r | n/r | n/r | 5.6 percentage (%) of total haemoglobin |
| Liraglutide 3.0 mgThe Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Obesity or overweight | 3.0 mg | n/r | n/r | placebo | n/r | n/r | n/r | 5.57 percentage (%) of total haemoglobin |
| Liraglutide OrlistatThe Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | 5.55 percentage (%) of total haemoglobin |
| Lixisenatide Lixisenatide24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years | T2D only | n/r | 24 | Efficacy | n/r | n/r | n/r | n/r | n/r |
| Lixisenatide Sitagliptin24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years | T2D only | n/r | 24 | Efficacy | n/r | n/r | n/r | n/r | n/r |
| Mazdutide 3/6 Milligrams (mg) MazdutideA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Mazdutide 10 mgA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity or overweight | 10 mg | 32 | n/r | placebo | n/r | 96.1% | n/r | n/r |
| Mazdutide 16 mgA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity or overweight | 16 mg | 32 | n/r | placebo | n/r | 92.23% | n/r | n/r |
| Mazdutide PlaceboA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity or overweight | n/r | 32 | n/r | This arm is placebo | n/r | 23.97% | n/r | n/r |
| Mazdutide 6 mgA Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Obesity or overweight | 6 mg | 32 | n/r | n/r | n/r | 67.64% | n/r | n/r |
| Oral Semaglutide Oral semaglutideOASIS 1 | Obesity or overweight | n/r | 1 | n/r | placebo | n/r | n/r | n/r | -0.2 Percentage of HbA1c |
| Oral Semaglutide Oral semaglutide placeboOASIS 1 | Obesity or overweight | n/r | 1 | n/r | This arm is placebo | n/r | n/r | n/r | 0.1 Percentage of HbA1c |
| Oral Semaglutide 25 mgOASIS 4 | Obesity or overweight | 25 mg | n/r | n/r | placebo | n/r | n/r | n/r | -0.3 Percentage of HbA1c |
| Oral Semaglutide Oral semaglutide placeboOASIS 4 | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | 0 Percentage of HbA1c |
| Oral Semaglutide 50 mgOASIS 2 | Obesity or overweight | 50 mg | 68 | ITT | placebo | n/r | n/r | n/r | -0.8 Change in HbA1c (%) |
| Oral Semaglutide oral semaglutide placebo once dailyOASIS 2 | Obesity or overweight | n/r | 68 | ITT | This arm is placebo | n/r | n/r | n/r | 0 Change in HbA1c (%) |
| TERN-601 250 mgFALCON | Obesity or overweight | 250 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| TERN-601 500 mgFALCON | Obesity or overweight | 500 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| TERN-601 750 mgFALCON | Obesity or overweight | 750 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| TERN-601 Matching PlaceboFALCON | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| CT-868 CT-868 PlaceboA Study of CT-868 in Type 1 Diabetes Mellitus | Obesity + T2D | n/r | 16 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| CT-868 1.8 mgA Study of CT-868 in Type 1 Diabetes Mellitus | Obesity + T2D | 1.8 mg | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| CT-868 4.1 mgA Study of CT-868 in Type 1 Diabetes Mellitus | Obesity + T2D | 4.1 mg | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| CT-868 6.6 mgA Study of CT-868 in Type 1 Diabetes Mellitus | Obesity + T2D | 6.6 mg | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| HM15211 HM15211A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD | NAFLD | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| HM15211 PlaceboA Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD | NAFLD | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Pramlintide Placebo-P + Placebo-MStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 360 mcg | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 5.0 mg | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Pramlintide 2.5 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 2.5 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 5.0 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide 1.25 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 1.25 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide 2.5 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 2.5 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide 5.0 mgStudy to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Obesity or overweight | 5.0 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide 1Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin | Obesity or overweight | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide 2Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide 3Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Pramlintide PlaceboA Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Pramlintide Pramlintide + MetreleptinA Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects | Obesity or overweight | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Pramlintide Pramlintide Acetate and PlaceboA Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Pramlintide Lead-In PeriodA Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 30 mg | 4 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 30 mg | 4 | n/r | placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 30 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 30 mg | 4 | n/r | placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 1.0 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 1.0 mg | 4 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 2.4 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 2.4 mg | 4 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 1.0 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 1.0 mg | 4 | n/r | placebo | n/r | n/r | n/r | n/r |
| Bimagrumab 2.4 mgSafety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese | Obesity or overweight | 2.4 mg | 4 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB16A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects | Obesity or overweight | n/r | 56 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects | Obesity or overweight | n/r | 56 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboA Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects | Obesity or overweight | n/r | 56 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboA Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects | Obesity or overweight | n/r | 28 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program | Obesity or overweight | n/r | 56 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboA Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program | Obesity or overweight | n/r | 56 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB32A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes | Obesity + T2D | n/r | 56 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboA Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes | Obesity + T2D | n/r | 56 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + NB medicationBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment | Obesity or overweight | n/r | 16 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + PlaceboBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment | Obesity or overweight | n/r | 16 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medicationPharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) | Obesity or overweight | n/r | 16 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion BWL + PlaceboPharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) | Obesity or overweight | n/r | 16 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion NB medicationBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy | Obesity or overweight | n/r | 16 | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboBehavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy | Obesity or overweight | n/r | 16 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone+Bupropion MedicationPharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboPharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion Naltrexone/BupropionCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Naltrexone And Bupropion PlaceboCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Orlistat Intensive Lifestyle Mod. InterventionFIT-PLESE | Infertility, Female | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Orlistat Standard Lifestyle InterventionFIT-PLESE | Infertility, Female | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Orlistat PlaceboSafety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases | Obesity + T2D | n/r | 12 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Orlistat OrlistatSafety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases | Obesity + T2D | n/r | 12 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 LowStudy of VI-0521 Compared to Placebo in Treatment of Obesity in Adults | Obesity or overweight | n/r | 56 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 TopStudy of VI-0521 Compared to Placebo in Treatment of Obesity in Adults | Obesity or overweight | n/r | 56 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate PlaceboStudy of VI-0521 Compared to Placebo in Treatment of Obesity in Adults | Obesity or overweight | n/r | 56 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 TopA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate VI-0521 MidA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate TPM 46A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate TPM 92A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate PHEN 7.5A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate PHEN 15A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate PlaceboA Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults | Obesity or overweight | n/r | 28 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 12SMART | Obesity or overweight | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate LSMT 24SMART | Obesity or overweight | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Phentermine & TopiramateAdjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds | Obesity or overweight | n/r | 12 | n/r | placebo | n/r | n/r | n/r | 0.05 Percentage of glycated hemoglobin |
| Phentermine And Topiramate Placebo DrugsAdjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds | Obesity or overweight | n/r | 12 | n/r | This arm is placebo | n/r | n/r | n/r | 0.1 Percentage of glycated hemoglobin |
| Phentermine And Topiramate SemaglutideA Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America | Obesity or overweight | n/r | 52 | n/r | n/r | n/r | n/r | n/r | n/r |
| Phentermine And Topiramate Other anti-obesity medicationA Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America | Obesity or overweight | n/r | 52 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SetmelanotideLong Term Extension Trial of Setmelanotide | Obesity or overweight | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide PlaceboA Trial of Setmelanotide in Acquired Hypothalamic Obesity | Obesity or overweight | n/r | 52 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Setmelanotide SetmelanotideA Trial of Setmelanotide in Acquired Hypothalamic Obesity | Obesity or overweight | n/r | 52 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide (Double-Blind)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide Placebo (Double-Blind)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide (Open-label)Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide Pivotal CohortSetmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | Bardet Biedl Syndrome (BBS); Alström Syndrome... | n/r | 52 | n/r | n/r | n/r | -5.21% | n/r | n/r |
| Setmelanotide 2 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 2 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 2.5 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 3 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 3 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 20 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 20 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 25 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 25 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 3 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 3 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 30 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 30 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 20 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 20 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 25 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 25 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 30 mgPhase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Bardet-Biedl Syndrome; POMC Deficiency | 30 mg | 1 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SetmelanotideSetmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | Obesity or overweight | n/r | 12 | n/r | n/r | n/r | -12.34% | n/r | n/r |
| Setmelanotide SetmelanotideSetmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity | Obesity or overweight | n/r | 12 | n/r | n/r | n/r | -25.83% | n/r | n/r |
| Setmelanotide Setmelanotide: PPL GroupSetmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | Obesity or overweight | n/r | 2 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Setmelanotide: BBS GroupSetmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | Obesity or overweight | n/r | 2 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide 16p11.2 CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide AS CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide BBS CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide MC4R CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Heterozygous CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SH2B1 CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SMS CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide SRC1 CohortSetmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Obesity or overweight | n/r | 16 | n/r | n/r | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 1: Setmelanotide (Open-Label)DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | Obesity or overweight | n/r | 16 | n/r | placebo | n/r | -3.94% | n/r | n/r |
| Setmelanotide Stage 2: Setmelanotide (Double-Blind)DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | Obesity or overweight | n/r | 16 | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide Stage 2: Placebo (Double-Blind)DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | Obesity or overweight | n/r | 16 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Setmelanotide PlaceboPhase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Setmelanotide SetmelanotidePhase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide PlaceboPhase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Setmelanotide 0.5 mgPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | Prader-Willi Syndrome | 0.5 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide 1.5 mgPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | Prader-Willi Syndrome | 1.5 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide 2.5 mgPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | Prader-Willi Syndrome | 2.5 mg | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Setmelanotide PlaceboPhase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome | Prader-Willi Syndrome | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Sibutramine SibutramineSCOUT | Obesity or overweight | n/r | n/r | n/r | placebo | n/r | n/r | n/r | n/r |
| Sibutramine PlaceboSCOUT | Obesity or overweight | n/r | n/r | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
| Tesofensine placebo arm48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO) | Obesity or overweight | n/r | 48 | n/r | This arm is placebo | n/r | n/r | n/r | n/r |
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.